You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Mallinckrodt
Medtronic
Harvard Business School
Merck

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Litigation Details for SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-08-02 117 certain terms contained with U.S. Patent 6,773,720 (the “ ’720 Patent”) pursuant to Markman v. Westview…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history…construction for a given patent are binding on later district courts analyzing the same patent. See Key Pharms…district courts of the same terms in the same patent or patent family are highly relevant and persuasive…to “simple dispersion” elsewhere in the patent, (’720 Patent, col. 1 l. 53), signifying that dispersion External link to document
2018-05-08 369 Order product that infringes U.S. Patent No. 6,773,720 ("the '720 patent"); WHEREAS, Defendants…;720 patent; WHEREAS, Defendants sought a declaratory judgment that the '720 patent is invalid…withdrew their claims of invalidity of the '720 patent. NOW, THEREFORE, Plaintiffs hereby request…its amendments, does not infringe the '720 patent; 2) Defendants' claims of invalidity… 2015 21 May 2018 1:15-cv-02865 830 Patent None District Court, D. New Jersey External link to document
2018-10-11 394 covered by U.S. Patent Number 6,773,720 (“ ‘720 patent”).2   Claim 1 of the ‘720 patent recites a  controlled‐release… On 22 April 2015, plaintiff Shire filed a patent infringement suit against defendants Amneal (“the…party. 2 According to the Orange Book, the ‘720 patent expires 8 Jun 2020.     …applications before the FDA, Shire  filed similar patent infringement cases against these ANDA applicants…this nor any other ANDA case involving the ’720 patent can be categorized as  an unqualified prevail.   External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKinsey
Johnson and Johnson
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.